Daré Bioscience, Inc. (DARE) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DARE Revenue Growth
Revenue Breakdown (FY 2024)
DARE's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
DARE Revenue Analysis (2013–2024)
As of May 8, 2026, Daré Bioscience, Inc. (DARE) generated trailing twelve-month (TTM) revenue of $-57,130, reflecting significant decline in growth of -94.6% year-over-year. The most recent quarter (Q3 2025) recorded $2,262 in revenue.
Looking at the longer-term picture, DARE's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.0 million in 2022.
Revenue diversification analysis shows DARE's business is primarily driven by License And Collaboration Revenues (100%), and Royalty Revenue (0%). With over half of revenue concentrated in License And Collaboration Revenues, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TPVG, EVAX (+125.8% YoY), and CODA (+33.2% YoY), DARE has underperformed the peer group in terms of revenue growth. Compare DARE vs TPVG →
DARE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DARECurrent | $-57,130 | -94.6% | - | -239692.2% | |
 TPVG | $97M | - | - | 77.9% | |
 EVAX | $8M | +125.8% | - | -122.7% | |
 CODA | $27M | +33.2% | +5.8% | 17.1% | |
 ANIP | $883M | +43.8% | +33.5% | 12.6% |
DARE Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10K | -99.7% | $-14,295,424 | -146110.2% | $-23,451,485 | -239692.2% |
| 2023 | $2.8M | -71.9% | $-18,830,189 | -670.6% | $-30,939,880 | -1101.9% |
| 2022 | $10.0M | - | $-20,142,217 | -201.4% | $-31,385,488 | -313.9% |
| 2021 | $0 | - | $-100,000 | - | $-39,068,512 | - |
| 2020 | $0 | - | $-83,333 | - | $-27,402,257 | - |
| 2019 | $0 | - | $-11,137 | - | $-14,344,880 | - |
| 2018 | $0 | - | $-2,440 | - | $-16,882,000 | - |
| 2017 | $0 | -100.0% | $0 | - | $-11,180,000 | - |
| 2016 | $766K | - | $366K | 47.8% | $-37,154,000 | -4850.4% |
| 2015 | $0 | -100.0% | $-192,000 | - | $-37,172,000 | - |
See DARE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DARE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DARE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDARE — Frequently Asked Questions
Quick answers to the most common questions about buying DARE stock.
Is DARE's revenue growth accelerating or slowing?
DARE revenue declined -94.6% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $-57130.00. This reverses the prior growth trend.
What is DARE's long-term revenue growth rate?
Daré Bioscience, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -94.6% is below this long-term average.
How is DARE's revenue distributed by segment?
DARE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.